Key result
Fluoropyrimidine chemotherapy was associated with a 7.7% absolute reduction in 1-year all-cause mortality compared to alternative management, outweighing a 0.9% absolute increase in cardiovascular events.
Why the study?
Patients with gastrointestinal cancer and cardiovascular disease often receive alternative treatment due to cardiotoxicity concerns with first-line fluoropyrimidines.
Does fluoropyrimidine chemotherapy reduce all-cause mortality and increase the risk of acute cardiovascular events in patients with gastrointestinal cancer?
Observational (n=103,110)
Yes
Does fluoropyrimidine chemotherapy reduce all-cause mortality and increase the risk of acute cardiovascular events in patients with gastrointestinal cancer?
In patients with gastrointestinal cancer, the substantial 1-year survival benefit of fluoropyrimidine chemotherapy significantly outweighs the small absolute increased risk of cardiac arrhythmias and arrest.
Answers are grounded in this paper and cite their sources.
May support fluoropyrimidine use in GI cancer despite small CV risk increase; leaves open causal effects pending randomized data.
BACKGROUND: Fluoropyrimidine chemotherapy is administered first-line for many gastrointestinal cancers. However, patients with cardiovascular disease commonly receive alternative treatment due to cardiotoxicity concerns. OBJECTIVES: This study sought to assess the risks of all-cause mortality and acute cardiovascular events with fluoropyrimidine treatment. METHODS: We conducted an observational cohort study applying a target trial emulation framework to linked national cancer, cardiac, and hospitalization registry data from the Virtual Cardio-Oncology Research Initiative. Adults diagnosed with tumors eligible for fluoropyrimidine-based chemotherapy as first-line therapy were included. All-cause mortality and a composite of hospitalization for acute cardiovascular events (acute coronary syndrome, heart failure, cardiac arrhythmia, cardiac intervention, cardiac arrest, and cardiac death) were compared in patients treated with fluoropyrimidine-based chemotherapy vs alternative management. Adjusted, weighted pooled logistic regression models were used to estimate the 1-year risk difference (RD). RESULTS: Among 103,110 patients (mean age 69.7 years, 59% male), the absolute risk of death at 1 year was significantly lower in fluoropyrimidine-treated patients (RD: -7.7%; 95% CI: -8.7% to -6.7%) with a small increased risk of acute cardiovascular events (RD: 0.9%; 95% CI: 0.0% to 1.9%). This was primarily due to arrhythmias (RD: 0.8%; 95% CI: 0.1% to 1.6%) and cardiac arrest (RD: 0.3%; 95% CI: 0.1% to 0.5%), with no increased risk of acute coronary syndromes including in the subgroup of patients with pre-existing coronary artery disease. CONCLUSIONS: The markedly improved overall survival with fluoropyrimidines in patients with gastrointestinal cancer significantly outweighs the small risk of cardiac arrhythmia and arrest. Oncologists should take this into consideration for decision making to avoid undue clinical conservatism, particularly in patients with cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Abiodun et al. (2025) conducted an observational in Gastrointestinal cancer (esophageal, gastric, colorectal) (n=103,110). Fluoropyrimidine-based chemotherapy vs. Alternative management (no fluoropyrimidine chemotherapy) was evaluated on 1-year all-cause mortality (RR 0.85, 95% CI 0.83 to 0.86). Fluoropyrimidine chemotherapy was associated with a 7.7% absolute reduction in 1-year all-cause mortality compared to alternative management, outweighing a 0.9% absolute increase in cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: